Abstract
Treating heart failure is one of the greatest unmet needs in cardiovascular medicine today. Overall survival is poor and 50% of patients die within 5 years of their initial diagnosis. Heart failure is a heterogeneous syndrome and a one-size-fits-all approach is ineffective. Therefore, in my thesis I used biomarkers to 1. Show that patients with heart failure and a preserved ejection fraction are subject to more inflammation, which can be a key treatment target and 2. Identified clinical relevant subgroups with differences in response to treatment using machine learning based approaches.
Original language | English |
---|---|
Qualification | Doctor of Philosophy |
Awarding Institution |
|
Supervisors/Advisors |
|
Award date | 17-Sept-2018 |
Place of Publication | [Groningen] |
Publisher | |
Print ISBNs | 978-94-034-1064-7 |
Electronic ISBNs | 978-94-034-1063-0 |
Publication status | Published - 2018 |